Cocrystal Pharma, Inc. has recently submitted its quarterly report, detailing its financial performance for the third quarter of 2026. This filing is significant as it provides insights into the company's financial health and strategic direction within the competitive pharmaceutical industry.

Founded in Bothell, Washington, Cocrystal Pharma operates in the pharmaceutical preparations sector, classified under SIC 2834. The company trades on the Nasdaq under the ticker symbol COCP. Cocrystal has been actively engaged in developing antiviral therapeutics, particularly targeting viral infections.

The recent filing, dated November 16, 2026, reveals that the company is continuing its efforts to advance its clinical programs. However, specific financial metrics and results were not disclosed in the filing. The document indicates that the company is navigating various challenges while striving to innovate and expand its product offerings.

While the filing does not provide detailed financial figures, it emphasizes Cocrystal's commitment to its research and development initiatives. This focus is crucial as the pharmaceutical industry remains highly competitive, with numerous companies vying for market share in antiviral treatments.

As Cocrystal Pharma continues to progress, stakeholders, including investors and industry analysts, will be keenly watching for further updates and developments. The filing does not specify what actions the company will take next, leaving questions about its future strategies and potential collaborations unanswered.